SARS-CoV-2 infection, gut dysbiosis, and heterogeneous clinical results of hydroxychloroquine on COVID-19 therapy—Is there a link?

Balmant, Bianca Depieri; Torrinhas, Raquel Susana; Rocha, Ilanna Marques Gomes da; Fonseca, Danielle Cristina; Formiga, Francisco Fellipe Claudino; Bonfá, Eloísa; Borba, Eduardo Ferreira; Waitzberg, Dan Linetzky

doi:10.1016/j.nut.2020.111115

Cited by 9 publications

(11 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Gastrointestinal disturbances are often associated with respiratory infections or to secondary complications, and the gut-lung axis, a hypothetical bidirectional pathway which works via biochemical and immunologic systemic signalling molecules, is possibly involved in the pathophysiology. Among the perturbing factors of the gut microbial environment, respiratory viral infections, including COVID-19, can play a relevant role[ 48 ]. As previously mentioned, an impairment of the gut microbiota composition, which is frequently associated to a dysregulation of the overall intestinal homeostasis and gut-brain axis, can participate to the development and maintaining of IBS[ 39 , 41 , 42 ].…”

Section: Covid-19 and Its Management: What Are The Possible Triggers Of Ibs?mentioning

confidence: 99%

“…Hydroxychloroquine was initially used as an antimalarial, but, subsequently, it has been used as a disease-modifying anti-rheumatic drug to treat rheumatic disorders due to its immunomodulatory properties[ 75 ]. The impact of this medication on the human gut microbiota has been assessed by Balmant et al [ 48 ] in patients affected by systemic lupus erythematosus. They reported that the use of this drug is associated to different degrees of dysbiosis with a dose-dependent effect[ 48 ].…”

Section: Covid-19 and Its Management: What Are The Possible Triggers Of Ibs?mentioning

confidence: 99%

“…The impact of this medication on the human gut microbiota has been assessed by Balmant et al [ 48 ] in patients affected by systemic lupus erythematosus. They reported that the use of this drug is associated to different degrees of dysbiosis with a dose-dependent effect[ 48 ].…”

Section: Covid-19 and Its Management: What Are The Possible Triggers Of Ibs?mentioning

confidence: 99%

See 2 more Smart Citations

COVID-19 as a trigger of irritable bowel syndrome: A review of potential mechanisms

Settanni¹,

Ianiro²,

Ponziani³

et al. 2021

WJG

View full text Add to dashboard Cite

In December 2019 a novel coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), started spreading from Wuhan city of Chinese Hubei province and rapidly became a global pandemic. Clinical symptoms of the disease range from paucisymptomatic disease to a much more severe disease. Typical symptoms of the initial phase include fever and cough, with possible progression to acute respiratory distress syndrome. Gastrointestinal manifestations such as diarrhoea, vomiting and abdominal pain are reported in a considerable number of affected individuals and may be due to the SARS-CoV-2 tropism for the peptidase angiotensin receptor 2. The intestinal homeostasis and microenvironment appear to play a major role in the pathogenesis of COVID-19 and in the enhancement of the systemic inflammatory responses. Long-term consequences of COVID-19 include respiratory disturbances and other disabling manifestations, such as fatigue and psychological impairment. To date, there is a paucity of data on the gastrointestinal sequelae of SARS-CoV-2 infection. Since COVID-19 can directly or indirectly affect the gut physiology in different ways, it is plausible that functional bowel diseases may occur after the recovery because of potential pathophysiological alterations (dysbiosis, disruption of the intestinal barrier, mucosal microinflammation, post-infectious states, immune dysregulation and psychological stress). In this review we speculate that COVID-19 can trigger irritable bowel syndrome and we discuss the potential mechanisms.

show abstract

Section: Covid-19 and Its Management: What Are The Possible Triggers Of Ibs?mentioning

confidence: 99%

Section: Covid-19 and Its Management: What Are The Possible Triggers Of Ibs?mentioning

confidence: 99%

See 1 more Smart Citation

COVID-19 as a trigger of irritable bowel syndrome: A review of potential mechanisms

Settanni¹,

Ianiro²,

Ponziani³

et al. 2021

WJG

View full text Add to dashboard Cite

show abstract

“…The dysbiosis in gut microbiome mainly exists when the diversity of microorganism is decreased, 297 but the dysbiosis of human-associated microbiota can also show as a change in the microbial composition. Enaud et al described that the gut and lungs have potential communications involving the microbiome via the gut-lung axis.…”

Section: New Biomarkers-based Laboratory Findings For Covid-19 Detectionmentioning

confidence: 99%

“…296 The gut microbiome has potential protective effects in the COVID-19 infection due to the decrease in several bacteria that are correlated with increasing cytokines and chemokines (such as TNF-α, CXCL10, CCL2, and IL-10) involved in overaggressive inflammation. 296 The dysbiosis in gut microbiome mainly exists when the diversity of microorganism is decreased, 297 but the dysbiosis of human-associated microbiota can also show as a change in the microbial composition. Enaud et al described that the gut and lungs have potential communications involving the microbiome via the gut-lung axis.…”

Section: Human Microbiome As a Potential Markermentioning

confidence: 99%

Applications of laboratory findings in the prevention, diagnosis, treatment, and monitoring of COVID-19

Meng

Guo

Zhou

et al. 2021

Sig Transduct Target Ther

View full text Add to dashboard Cite

The worldwide pandemic of coronavirus disease 2019 (COVID-19) presents us with a serious public health crisis. To combat the virus and slow its spread, wider testing is essential. There is a need for more sensitive, specific, and convenient detection methods of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Advanced detection can greatly improve the ability and accuracy of the clinical diagnosis of COVID-19, which is conducive to the early suitable treatment and supports precise prophylaxis. In this article, we combine and present the latest laboratory diagnostic technologies and methods for SARS-CoV-2 to identify the technical characteristics, considerations, biosafety requirements, common problems with testing and interpretation of results, and coping strategies of commonly used testing methods. We highlight the gaps in current diagnostic capacity and propose potential solutions to provide cutting-edge technical support to achieve a more precise diagnosis, treatment, and prevention of COVID-19 and to overcome the difficulties with the normalization of epidemic prevention and control.

show abstract

The Impact of Gut Microbiota on the Immune Response to Vaccination

Bajoria

Szczelkun

Dinse

et al. 2022

Comprehensive Gut Microbiota

View full text Add to dashboard Cite

SARS-CoV-2 infection, gut dysbiosis, and heterogeneous clinical results of hydroxychloroquine on COVID-19 therapy—Is there a link?

Cited by 9 publications

References 37 publications

COVID-19 as a trigger of irritable bowel syndrome: A review of potential mechanisms

COVID-19 as a trigger of irritable bowel syndrome: A review of potential mechanisms

Applications of laboratory findings in the prevention, diagnosis, treatment, and monitoring of COVID-19

The Impact of Gut Microbiota on the Immune Response to Vaccination

Contact Info

Product

Resources

About